Last reviewed 2026-04-20 · How we verify

intravitreous aflibercept

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients (PHASE4)
• A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV) (PHASE4)
• A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) (PHASE2)
• A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy (PHASE3)
• DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME (PHASE3)
• Anti-VEGF Treatment for Prevention of PDR/DME (PHASE3)
• Anti-VEGF vs. Prompt Vitrectomy for VH From PDR (PHASE2, PHASE3)
• Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• intravitreous aflibercept CI brief — competitive landscape report
• intravitreous aflibercept updates RSS · CI watch RSS
• Jaeb Center for Health Research portfolio CI